StockData
QuidelOrtho Corp logo

QuidelOrtho Corp (QDEL) stock

QDELNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends January 1
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/3063% below fair value
$9.57−0.30 (-3.04%)

Close on Nov 18, 2026Market cap $656.27MP/E –Yield –

QuidelOrtho operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

QuidelOrtho's operating income for the twelve months ending Sep 27, 2026 was -$127.40M. For fiscal 2025 it was -$919.20M. The highest annual figure on record is $1.06B in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 28, 2025-$919.20M–
FY2024Dec 29, 2024-$1.96B-1509.7%
FY2023Dec 31, 2023$139.10M-83.5%
FY2022Jan 1, 2023$843.70M-6.9%
FY2021Jan 2, 2022$906.00M-14.6%
FY2020Jan 3, 2021$1.06B–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 27, 2026-$7.50M–
Q2 FY2026Jun 28, 2026-$21.80M–
Q1 FY2026Mar 29, 2026-$31.80M-197.5%
Q4 FY2025Dec 28, 2025-$66.30M–
Q3 FY2025Sep 28, 2025-$704.80M-4798.7%
Q2 FY2025Jun 29, 2025-$180.70M–
Q1 FY2025Mar 30, 2025$32.60M–
Q4 FY2024Dec 29, 2024-$100.40M-350.4%
Q3 FY2024Sep 29, 2024$15.00M-43.0%
Q2 FY2024Jun 30, 2024-$117.50M–
Q1 FY2024Mar 31, 2024-$1.76B-1865.1%
Q4 FY2023Dec 31, 2023$40.10M-53.6%
Q3 FY2023Oct 1, 2023$26.30M-53.7%
Q2 FY2023Jul 2, 2023-$26.90M-133.8%
Q1 FY2023Apr 2, 2023$99.60M-84.0%
Q4 FY2022Jan 1, 2023$86.50M-77.0%
Q3 FY2022Oct 2, 2022$56.80M-79.8%
Q2 FY2022Jul 3, 2022$79.70M+242.1%
Q1 FY2022Apr 3, 2022$620.70M–
Q4 FY2021Jan 2, 2022$376.70M–
Q3 FY2021Oct 3, 2021$281.80M–
Q2 FY2021Jul 4, 2021$23.30M–

More QuidelOrtho figures

See a number that looks wrong?